Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 9/30/2015 | 6/30/2015 | 3/31/2015 | |
|---|---|---|---|---|
| Revenue | $1,289 | $1,562 | $1,342 | $1,068 |
| % Growth | -17.5% | 16.4% | 25.7% | – |
| Cost of Goods Sold | $513 | $497 | $535 | $551 |
| Gross Profit | $776 | $1,065 | $807 | $517 |
| % Margin | 60.2% | 68.2% | 60.2% | 48.4% |
| R&D Expenses | $1 | $1 | $3 | $7 |
| G&A Expenses | $0 | $1,054 | $0 | $0 |
| SG&A Expenses | $1,233 | $1,054 | $1,175 | $1,785 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$91 | $27 | $0 | $0 |
| Operating Expenses | $1,143 | $1,082 | $1,179 | $1,792 |
| Operating Income | -$367 | -$17 | -$371 | -$1,275 |
| % Margin | -28.5% | -1.1% | -27.6% | -119.4% |
| Other Income/Exp. Net | -$238 | -$221 | -$175 | -$404 |
| Pre-Tax Income | -$605 | -$238 | -$546 | -$1,678 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$581 | -$238 | -$546 | -$1,678 |
| % Margin | -45.1% | -15.2% | -40.7% | -157.2% |
| EPS | -0.021 | -0.01 | -0.02 | -0.06 |
| % Growth | -114% | 50% | 66.7% | – |
| EPS Diluted | -0.021 | -0.01 | -0.02 | -0.06 |
| Weighted Avg Shares Out | 27,218 | 27,457 | 26,948 | 26,769 |
| Weighted Avg Shares Out Dil | 27,218 | 27,457 | 26,948 | 26,769 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $238 | $265 | $267 | $404 |
| Depreciation & Amortization | $54 | $52 | $58 | $68 |
| EBITDA | -$313 | $79 | -$222 | -$1,207 |
| % Margin | -24.3% | 5.1% | -16.5% | -113% |